So far, studies have reported: Phase 2 (48 weeks): up to 24.2% average weight loss Phase 3 TRIUMPH-4 topline (68 weeks): 28.7% average weight loss (press release) What that looks like: If you start at 100 kg : 24.2% 24 kg average loss 28.7% 29 kg average loss Side effects and safety signals (what we know so far) Phase 2 (peer-reviewed) In the phase 2 trial, the most common adverse events were gastrointestinal and dose-related, typically mild to moderate
The localization of this receptor is highly specific
Bbs5 / mice were characterized by hyperphagia, learning deficits, glucose/insulin intolerance, and disrupted metabolic hormones, phenocopying human BBS
GLP-1s and fertility GLP-1s can increase fertility and may make oral contraceptives less effective
Structure of the complex of an iminopyridinedione protein tyrosine phosphatase 4A3 phosphatase inhibitor with human serum albumin
Plan for at least 20 weeks of titration plus 12-28 weeks of maintenance at your target dose
